666 results about "Drug concentration" patented technology

The invention discloses a method for in vitro slow release performance evaluation of a slow and controlled release preparation based on the overflow principle. A container with an upper outlet and a lower outlet is adopted to serve as a release tank, a to-be-detected medicine and a dissolution medium are placed in the release tank, a stirring device is adopted in the release tank to perform stirring, and the dissolution medium is added from the lower outlet of the release tank through a peristaltic pump; the dissolution medium dissolved with the medicine is taken away through the overflow from the upper outlet so as to offset medicine absorption or metabolism, and the slow and controlled release speed of the medicine, the total medicine overflow quantity and the total release amount are calculated by measuring the concentration of the medicine contained in the dissolution medium flowing out, the volume of the release tank and the overflow quantity. According to the method, the releasing degree of the slow and controlled release medicine can be evaluated accurately, the effective medicine release time of the slow and controlled release preparation is evaluated, and slow release performances of the slow and controlled release preparation are evaluated comprehensively.

The invention discloses an intelligent dosing system and method based on machine learning, and the method comprises the steps: S1, collecting fluidized bed operation parameters and water quality characteristic data in real time, including water flow dynamic parameters, water quality index parameters and particle morphology parameters, and constructing a time sequence characteristic database; s2, constructing a dynamic dosing model based on the fluidized bed by using data in the time sequence characteristic database, and performing joint prediction on the medicament type, the dosing amount and the operation parameters; s3, according to a prediction result output by the model, controlling the agent dosage, the agent concentration, the water flow speed and the aeration intensity; and S4, monitoring the fluidized bed and dosing control parameters in real time, and dynamically correcting the fluidized bed parameters in combination with the effluent turbidity of the fluidized bed and the particle sedimentation efficiency, so as to solve the problems that the sewage treatment effect in the prior art is poor, and medicament waste, substandard treatment and secondary environmental pollution are possibly caused.

The invention relates to the technical field of drug concentration detection, and relates to a clinical pharmaceutical blood concentration detection method, which comprises the following steps: capturing drug molecules in a blood sample based on a micro-fluidic chip, enabling a sensor to detect the drug molecules and combine with the surface of the drug molecules, and collecting high-sensitivity blood reaction data. According to the method, main variables in data are identified and utilized by adopting a principal component analysis method, so that the complexity of spectral data is effectively reduced, meanwhile, the most critical information for calculating the drug concentration is reserved, the data processing flow is optimized, the analysis speed and efficiency are improved, and the prediction of the drug concentration is more accurate; according to the method, more reliable data support is provided for clinic, the data is smoothed through the moving average algorithm, random fluctuation caused by sampling errors or external variables is reduced, the overall quality and credibility of the data are improved, errors can be obviously reduced, and therefore doctors are supported to conduct more accurate medicine dosage adjustment and curative effect evaluation.

The invention provides an integrated dynamic drug metabolism monitoring and early warning system, and relates to the technical field of drug metabolism monitoring and early warning, the integrated dynamic drug metabolism monitoring and early warning system comprises a data acquisition module, a data processing module, a model construction module, an early warning mechanism module and a user interaction module, the data acquisition module is composed of an optical sensor, a chemical sensor and an electrophysiological sensor, according to the system, the concentration of drugs and related physiological parameters are monitored in real time, different types of biological signals are captured, and the sensitivity and selectivity of the sensors are considered in the design of the data acquisition module so as to ensure the stability and accuracy in different physiological states. Drug concentration and physiological parameters are monitored in real time from multiple dimensions, sensors select and cooperate to form an efficient acquisition network according to performance expression, data quality is optimized in combination with a multi-source data fusion algorithm (such as Kalman filtering and a weighted average method), and a data processing module adopts a statistical analysis algorithm to clean standardized data.

The invention relates to the technical field of anesthesia, and discloses a personalized anesthesia scheme generation method, which comprises the following steps: S1, extracting and coding patient features; s2, modeling a pharmacokinetic model; s3, drug concentration prediction; s4, applying a PD model; s5, performing uncertainty quantification; s6, predicting and outputting; s7, updating and feeding back parameters; s8, verifying the model; in the personalized anesthesia scheme generation process, firstly, effective feature extraction and coding are carried out on multi-modal data of a patient; according to the personalized anesthesia scheme generation method, efficient feature extraction is carried out on multi-modal data (such as electronic health records, genome information and real-time monitored vital signs) through VAE and other deep learning methods, and the differences of patients in the aspects of physique, drug metabolism capability, gene background and the like can be fully described; therefore, the optimal anesthetic medication strategy is customized for each patient.

The invention discloses a hospital automatic drug delivery system with controllable drug concentration, comprising: a drug delivery device for delivering drugs into the body of a patient; the concentration sensor is used for monitoring the concentration index of the medicine in the body of the patient in real time; the control unit is used for receiving the signal from the drug release calculation module and controlling the conveying rate of the drug delivery device according to a set drug concentration range; the medicine release calculation module is used for calculating the release amount and the delivery rate of the medicine according to the preset value and the medicine concentration obtained by the feedback module, and generating a control instruction; and the feedback module is used for calculating the drug concentration according to the measurement result of the concentration sensor. By controlling the concentration of the drug in the target area in the drug delivery process, it is guaranteed that the drug can be stably released and delivered to the target area under the preset concentration.

The invention discloses a preparation method of a novel ginseng exosome nano drug delivery system, and mainly relates to the field of functional medical materials. Comprising the following steps: S1, preparing a ginseng exosome crude extract; s2, centrifuging the crude extract and taking supernate; s3, centrifuging the supernate, and taking the precipitate to obtain an exosome resuspension; s4, preparing a purified ginseng exosome; s5, preparing kaempferol nano-enzyme freeze-dried powder; s6, mixing the ginseng exosome solution with the kaempferol nano-enzyme freeze-dried powder to obtain a ginseng exosome kaempferol nano-enzyme mixed solution; and S7, separating the ginseng exosome loaded with the kaempferol nano enzyme to obtain the ginseng exosome nano delivery system. The preparation method has the beneficial effects that the plant active ingredient ginseng exosome is taken as a delivery carrier to carry the water-soluble kaempferol nano-enzyme, and the water-soluble kaempferol nano-enzyme and the ginseng exosome play a synergistic role, so that the effective loading capacity of the exosome on the medicine is improved, the concentration of the medicine is improved, and the preparation method plays a role in various diseases such as wounds and inflammation; the traditional Chinese medicine composition can be better applied to treatment of acute lung injury.

The invention provides a therapeutic drug monitoring kit and method and system, a magnetic bead extraction method is combined with LC-MS / MS detection to be applied to human blood drug concentration monitoring, a mixed magnetic bead solution containing phospholipid removal magnetic beads and to-be-detected drug adsorption magnetic beads is utilized to perform adsorption and extraction pretreatment on a to-be-detected drug in a sample, automatic treatment equipment is matched, and the concentration of the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug in the to-be-detected drug is detected. The pretreatment efficiency is high, the phospholipid content in the supernate is low, and the matrix effect and the chromatographic column washing pressure are greatly reduced. According to the therapeutic drug monitoring method provided by the invention, a unified pretreatment process is used, simultaneous extraction of multiple drugs is realized, and through a magnetic bead automatic extraction method, the pretreatment step of a sample can be rapidly completed, a therapeutic drug monitoring result can be rapidly obtained, the overall detection time is shortened, and the detection efficiency is improved. Therefore, a reliable laboratory examination basis is provided for individualized treatment.

Provided in the present invention is an analysis and detection method for simultaneously detecting tretinoin and tranexamic acid, and the use of the analysis and detection method. The method comprises: analyzing a sample to be tested comprising tretinoin and tranexamic acid by using an ultra-high performance liquid chromatography-triple quadrupole mass spectrum, so as to achieve the qualitative and quantitative detection of tretinoin and tranexamic acid. The analysis and detection method provided in the present invention has the characteristics of a high sensitivity and high precision, good repeatability, high accuracy, high stability, etc. The detection method of the present invention can be relatively easily transferred and applied to the detection of the two compounds in biological samples such as plasma and tissue homogenates, and can satisfy the requirements for drug concentration monitoring.

The invention discloses an LC-MS / MS detection method for a palbozuril monoclonal antibody drug in a blood sample, which comprises the following steps: enriching and purifying the palbozuril monoclonal antibody drug in serum and plasma by coupling an enrichment reagent I with magnetic beads, magnetically separating the enriched blood sample, discarding the supernatant, adding a buffer solution I for leaching, and adding a buffer solution II for diluting after leaching; the method comprises the following steps: carrying out high-temperature denaturation on a diluted blood sample, sequentially adding an internal standard and protease for enzymolysis, and then adopting a high performance liquid chromatography-tandem mass spectrometry to realize high-sensitivity rapid detection of the drug concentration of the palbozuril monoclonal antibody in the blood sample. In the pretreatment process, the steps of protein reduction and alkylation are removed, the proteolysis time is shortened, the whole process is simple, convenient and rapid, and multiple requirements of clinical detection on timeliness, accuracy and low detection cost can be met at the same time.

The invention relates to the technical field of pharmaceutical preparations, and provides a minoxidil film coating agent as well as a preparation method and application thereof. The minoxidil film coating agent provided by the invention comprises 40-60% of propylene glycol, 3-7% of polyvinyl alcohol, 20-30% of ethanol, 1-7% of minoxidil and the balance of water. According to the invention, propylene glycol is taken as a solvent, a plasticizer and a transdermal absorption enhancer, polyvinyl alcohol is taken as a film-forming material, and ethanol is taken as a volatile agent, after administration, ethanol is volatilized to promote film formation of polyvinyl alcohol, and propylene glycol enhances the plasticity of the formed film, so that the effect of reducing liquid medicine loss is achieved, the local medicine concentration is increased, and the bioavailability is improved. The minoxidil liniment disclosed by the invention has excellent skin permeability, can effectively convey a medicine to a required part, and can ensure that the medicine is released at a fixed position of the skin and is accurately administered in a medicine release process, so that the stimulation of liquid medicine flow to other parts is reduced, and a good treatment effect is achieved.

The invention discloses an administration agent in-vivo release and absorption visualization method based on a CFD-PBM coupling model. The method comprises the following steps: constructing a CFD model of a physiological environment of an injection site; establishing a population balance model (PBM) of the drug particles; the PBM is embedded into a CFD model solver, multi-scale coupling simulation is carried out, and a CFD-PBM coupling model is obtained; the three-dimensional visualization engine dynamically displays drug concentration distribution and particle behaviors; reversely adjusting preparation prescription parameters by using a multi-parameter optimization algorithm; and calibrating model parameters, and generating a key data report. According to the method, the prediction precision and the research and development efficiency can be remarkably improved, and the method is suitable for development of long-acting preparations such as microspheres and implants.

An infusion pump is configured to provide one or more context cues to a user while the user programs the infusion pump to deliver an infusion therapy. In some embodiments, the infusion pump includes a display configured to display a keypad and to receive input from a user, a processor in communication with the display, and a memory in communication with the processor. The memory stores instructions that cause a keypad sequence monitor to receive context parameters, the context parameters corresponding to a drug selection, a drug concentration selection, or a clinical care area in which the drug is to be infused. The keypad sequence monitor accesses a drug library using the context parameter to determine a valid parameter range corresponding to a range of values between lower and upper soft limit values stored in the drug library. The keypad sequence monitor is further configured to receive an treatment parameter value from the user and display one or more context cues upon determining that the received treatment parameter value is outside of a valid treatment parameter range, but would be within a valid treatment parameter range if one of the context parameters were changed.

The invention discloses a pioglitazone hydrochloride drug production environment monitoring and early warning method and system, and relates to the technical field of drug production environment monitoring. Comprising the following steps: collecting microbial samples in a production place, constructing a plurality of culture media according to the types of the microbial samples, obtaining environmental data of the production place in a current time period, including the concentration, humidity and temperature of a pioglitazone hydrochloride drug, and simulating an ecological environment outside different culture media based on the environmental data to reflect an actual production environment of the production place. According to the present invention, by collecting the microorganism sample of the production site and combining the environmental data (such as the pioglitazone hydrochloride drug concentration, the humidity and the temperature) of the current time period, the actual condition of the production environment can be accurately reflected, and by simulating the ecological environment and associating the biological characteristic data with the environmental data, the real-time monitoring of the production environment can be achieved. And real-time monitoring of microbial activity in a production environment is realized, so that potential safety hazards caused by a production place to organisms are monitored from the side.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

The invention provides a micro-fluidic chip capable of culturing oral squamous cell carcinoma organoid and a preparation method thereof, and relates to the technical field of micro-fluidic chips, the chip comprises a four-layer structure: the first layer is a closed layer, the second layer is a culture solution / drug pool layer (containing a concentration gradient injection channel and a slow flow channel), the third layer is a matrix culture pool layer, and the fourth layer is a matrix culture pool layer. The fourth layer is a matrigel inflow layer (containing an S-shaped flow channel); the second layer and the third layer are integrally formed, and all the layers are connected through oxygen plasma welding; the problems that in the prior art, matrigel is prone to shifting, drug gradient regulation and control is poor, operation is tedious, and adaptability is insufficient are solved, the matrigel and organoids can be stably fixed, the drug concentration gradient can be precisely regulated and controlled, the nutrition supply efficiency is enhanced, the structural integration level and operation convenience are improved, and the application prospect is wide. The method is suitable for oral squamous cell carcinoma organoid culture, drug screening and tumor mechanism research.

The invention relates to the technical field of detection and analysis, and discloses a nanoparticle for detecting the concentration of methotrexate as well as a preparation method and application of the nanoparticle. The nanoparticles disclosed by the invention comprise hairpin DNA which is connected with the gold nanoparticles and is provided with a marking group and aptamer chain DNA which can be specifically recognized by methotrexate, and the aptamer chain DNA and walking chain DNA are hybridized into double-chain DNA which is connected to a magnetic bead, on one hand, the concentration of MTX is measured by marking a DNA chain of a fluorophore and collecting a fluorescence signal; on the other hand, after sodium chloride is added into the gold nanoparticles without DNA protection, the color of the gold nanoparticles changes under a high-salt condition, and the concentration of MTX is measured by collecting ultraviolet values. According to the nanoparticles provided by the invention, all parts interact with one another, signals are amplified, the effect of double detection of MTX concentration is exerted, and a powerful strategy is provided for accurately mastering the drug concentration in real time and improving the treatment safety and effect.

The invention discloses an SERS (Surface Enhanced Raman Scattering) detection method for paclitaxel drug concentration in blood of a breast cancer patient, and belongs to the technical field of detection. The method comprises the following steps: performing acetonitrile two-step precipitation centrifugal treatment on a blood sample to obtain a detection sample; the method comprises the following steps: constructing a high-sensitivity SERS substrate (the volume ratio of gold nanoparticles to ethanol is 1: (90-100), and a film is formed on a water-cyclohexane interface) through self-assembly of gold nanoparticles on a liquid-liquid interface; the method comprises the following steps: dropwise adding a sample into a substrate, and detecting characteristic peaks of 1024cm <-1 > and 1053cm <-1 > by using a portable Raman spectrometer (785nm, 30mW, 0.5 s); and calculating the paclitaxel concentration in combination with a pre-established quantitative curve. The method is easy and convenient to operate and suitable for clinical bedside rapid monitoring.

The invention relates to the technical field of medicines, in particular to a dihydroergoline mesylate controlled release tablet and a preparation method thereof. The dihydroergoline mesylate controlled release tablet comprises a tablet core, an inner coating and an outer coating, wherein the tablet core is coated with the inner coating and the outer coating layer by layer; the weight ratio of the tablet core to the inner coating to the outer coating is 50: (6-8): (3-5); the dihydroergoline mesylate tablet solves the problem that the drug release rate of the existing dihydroergoline mesylate tablet is unstable, and realizes more uniform and predictable drug release characteristics. By optimizing preparation components and a preparation process, the controlled-release tablet disclosed by the invention can maintain stable drug concentration in vivo, and the treatment experience of a patient is improved.

The invention relates to the technical field of blood concentration detection by optical means, in particular to a clinical blood concentration detection method. The method comprises the following steps: acquiring the delay responsivity of spectral data to drug concentration and the change complexity of other wavebands except a preset characteristic waveband; further obtaining the interfered change credibility of the drug concentration; according to the morphological characteristics of the spectrum curve corresponding to each drug concentration in the preset characteristic wave band and the distribution difference characteristics of the data points between the corresponding spectrum curve and the preset spectrum curve in the preset characteristic wave band, obtaining the spectrum shape distortion of the spectrum curve corresponding to each drug concentration in the preset characteristic wave band; obtaining the processing beneficial confidence of the spectral data; filtering the spectral data to obtain filtered spectral data; and detecting the blood concentration. According to the method, interference components in spectrum detection are removed, so that the quality of spectrum data and the detection precision of the blood concentration are improved.

The embodiment of the invention provides a multi-dimensional data processing method and system for intelligent scoring of emergency patients. The method comprises the following steps: acquiring dynamic temperature data and humidity fluctuation data of a burn wound surface through a flexible wearable monitoring device; inputting the time sequence change of the dynamic temperature data into a temperature-drug release model to generate drug concentration distribution; constructing an infection diffusion map taking the anatomical structure as a topological reference, wherein the infection diffusion map comprises an edge attribute representing the flow direction of tissue fluid and a node attribute representing a necrotic region; combining the metabolic rate parameter in the node attribute and the fluid resistance parameter in the edge attribute, iteratively updating the infection propagation intensity, and generating a weight distribution diagram; matching burn depth grading standards according to geometric deformation characteristics and gradient attenuation trends of the weight distribution map, and generating infection risk dynamic scores integrated with drug concentration distribution feedback. According to the technical scheme provided by the embodiment of the invention, the multi-dimensional data processing efficiency and precision can be improved.

The application discloses a bacteriostatic and acne-removing microemulsion containing plant extracts and a preparation method thereof. The bacteriostatic and acne-removing microemulsion contains a microemulsion loaded with quercetin alone, a microemulsion loaded with sasanquasapernin alone, and a microemulsion loaded with quercetin and sasanquasapernin simultaneously. The bacteriostatic and acne-removing microemulsion containing plant extracts prepared by the application not only solves the problems of stickiness of camellia oil and poor solubility of quercetin, but also has a synergistic inhibitory effect on propionibacterium acnes, achieves the same high-efficiency bacteriostatic effect with a lower drug concentration, saves drug cost, reduces drug irritation, and expands the application of quercetin and sasanquasapernin in the cosmetic and pharmaceutical fields due to the rich pharmacological effect of the plant extracts, low side effect and safety. The microemulsion system prepared by the application is clear, transparent, uniform and stable, the preparation process is simple, the required energy is low, the cost is low, and the system is beneficial to commercial production.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention provides a neutron transport simulation method and device, a medium, equipment and a BNCT treatment system. The method comprises the following steps: setting a plurality of voxel grids; the voxel grids are various human tissue materials corresponding to different boron drug concentrations; performing off-line coding on each voxel grid to obtain a corresponding physical coding layer, wherein the physical coding layer is used for predicting a corresponding neutron outgoing flow and neutron flux distribution based on the neutron incoming flow of the voxel grid; acquiring a CT image of the target object, and matching the voxel grid according to the CT image and the boron medicine planned concentration to acquire a voxel model of the target object; the physical coding layers of all voxel grids in the voxel model are coupled online. According to the method, the physical coding layers of various voxel grids are generated in an off-line manner, and the corresponding neutron outgoing flow and neutron flux distribution can be quickly predicted based on the given neutron incoming flow; and coupling a plurality of voxel grids based on a patient individualized voxel model to quickly obtain neutron flux distribution in the voxel model.

The invention relates to the technical field of medicine detection, in particular to a detection method of sildenafil citrate tablets, which comprises the following steps: S1, placing contents and target samples with different water contents in a plurality of containers; s2, determining the drug concentration of each region based on the color development characteristics of the diffused image of the target sample in the container at different detection time points, and calculating the concentration gradient component and diffusion concentration gradient of the target sample; s3, measuring the total amount or the concentration of the residual medicine of the target sample in the plurality of containers in a preset time period so as to determine the residual degree of the target sample; and S4, determining the diffusion difference degree based on the diffusion concentration gradient and the residual degree, and evaluating the diffusion adaptability of the target sample based on the diffusion difference degree. The accuracy and depth of drug diffusion performance research are improved, reliable data support is further provided for drug research and development and quality control, and drug quality can be improved.

The present invention belongs to the field of drug research and development, and specifically discloses a method, storage chip and device for efficiently evaluating the efficacy of in vitro combined drug therapy. The present invention directly solves the problems of complexity and high cost of experiments and data processing in the existing drug development process by adopting an AI model and a simplified experimental mode. The AI ​​model optimizes concentration selection based on historical drug data, thereby reducing redundant concentrations and unnecessary number of experiments in the experiment, and improving the sensitivity and reliability of the evaluation. By simplifying the experimental design to single drug concentration point testing and a 3x3 combined drug matrix, the complexity and cost of the experiment are significantly reduced, while the speed of data processing and analysis is accelerated. The method disclosed in the present invention avoids excessive combined drug pre-testing by directly conducting single drug and 3x3 matrix combined drug testing, which can not only more effectively identify potential synergies between drugs, but also provide more accurate and practical data to support future clinical research.

The invention provides a stem cell exosome for overexpressing A beta degrading enzyme as well as a preparation method and application of the stem cell exosome. Specifically, the invention provides an application of the stem cell exosome overexpressing A beta degrading enzyme in preparation of drugs, and the drugs are used for at least one of the following: prevention, improvement or treatment of cognitive impairment related diseases; neuronal cell damage is improved; wherein the stem cells for overexpressing the A beta degrading enzyme are prepared through lentivirus transfection. According to the stem cell exosome overexpressing the A beta degrading enzyme, the content of the A beta degrading enzyme is obviously higher than that of the exosome prepared by a traditional method. Therefore, when the compound is prepared into a medicine for treating or preventing cognitive impairment related diseases, the medicine can be efficiently conveyed to the brain, and the concentration of the medicine in the brain is remarkably improved, so that the curative effect is enhanced, the dosage of the medicine can be reduced, the side effect is reduced, and the prognosis of brain diseases is effectively improved.

The invention relates to the technical field of traditional Chinese medicine plasters, in particular to a traditional Chinese medicine ointment for preventing relapse of infantile asthma and a preparation method thereof.The traditional Chinese medicine ointment is characterized by sequentially comprising a protective backing layer, a medicine storage layer, a controlled release film layer and an application bonding layer from top to bottom; the traditional Chinese medicine plaster provided by the invention overcomes the defect that the traditional oral traditional Chinese medicine is easily influenced by a first-pass effect and individual differences through an external transdermal administration mode, can continuously maintain efficient medicine concentration at an application part and realize long-acting slow release, and the synergistic effect of the nano micro-emulsion medicine carrying system and the controlled release film layer can realize the sustained release effect of the traditional Chinese medicine. According to the traditional Chinese medicine plaster disclosed by the invention, the stable release of effective components of the medicine is ensured, the penetration rate of the medicine on a skin barrier is also remarkably improved, so that the treatment depth and the action durability of the plaster are enhanced, and meanwhile, the traditional Chinese medicine plaster aims at the pathological mechanism of infantile asthma, relieves airway inflammation, reduces airway hyperresponsiveness and mucus secretion, and has a remarkable curative effect on infantile asthma. The acute attack frequency of asthma can be obviously reduced, and the remission period is prolonged.

The invention discloses a drug targeted delivery device and method, and belongs to the technical field of intelligent medical treatment. The device comprises the following modules: an intelligent targeted recognition module for accurately recognizing a gastric cancer specific molecular marker and improving the selectivity and specificity of targeted recognition in combination with a dynamic surface modification strategy; the microenvironment real-time monitoring module is used for monitoring key physiological parameters of the gastric cancer microenvironment in real time; the intelligent path planning module is used for dynamically calculating and optimizing a drug delivery path and realizing accurate drug positioning; the personalized drug administration regulation and control module is used for accurately predicting the drug dosage demand of an individual and dynamically and finely adjusting the drug administration amount in real time; the drug resistance risk management module is used for early warning a drug resistance risk in advance and automatically generating a personalized alternative drug administration strategy through multi-dimensional drug resistance analysis and real-time early warning; and the intelligent drug release module adopts a temperature-sensitive / pH-sensitive polymer shell layer and a nano valve to control drug release, so that precise gradient release of drug concentration is realized.

The invention relates to the field of drug concentration detection, in particular to a rapid tacrolimus drug concentration detection device based on a micro-fluidic chip. The detection device comprises a blood sampling area, a separation area, a liquid medicine storage area, a waste liquid storage area and a spectrograph, the separation area is used for separating a tacrolimus medicine in a blood sample solution, and a liquid medicine sample and a waste liquid sample are obtained; the spectrograph is used for collecting liquid medicine spectral data of the liquid medicine sample in the liquid medicine storage area and waste liquid spectral data of the waste liquid sample in the waste liquid storage area, and detecting the concentration of the tacrolimus medicine in the blood sample solution according to the liquid medicine spectral data and the waste liquid spectral data. According to the invention, the accuracy of detecting the concentration of the tacrolimus drug in the blood can be improved.